Petra Staubach Selected Research

Omalizumab (Xolair)

3/2022	Severe chronic spontaneous urticaria in children - treatment options according to the guidelines and beyond - a 10 years review.
1/2022	An open-label, proof-of-concept study of lirentelimab for antihistamine-resistant chronic spontaneous and inducible urticaria.
7/2021	Autoimmune Diseases Are Linked to Type IIb Autoimmune Chronic Spontaneous Urticaria.
1/2021	Expert consensus on practical aspects in the treatment of chronic urticaria.
10/2019	Ligelizumab for Chronic Spontaneous Urticaria.
1/2019	Antihistamine-resistant chronic spontaneous urticaria: 1-year data from the AWARE study.
1/2019	Omalizumab normalizes the gene expression signature of lesional skin in patients with chronic spontaneous urticaria: A randomized, double-blind, placebo-controlled study.
12/2018	Total IgE levels are linked to the response of chronic spontaneous urticaria patients to omalizumab.
7/2018	The Urticaria Activity Score-Validity, Reliability, and Responsiveness.
1/2018	Omalizumab treatment in patients with chronic inducible urticaria: A systematic review of published evidence.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Petra Staubach Research Topics

Disease

24	Chronic Urticaria 03/2022 - 07/2009
13	Urticaria (Hives) 03/2022 - 07/2011
10	Pruritus (Itching) 10/2020 - 03/2010
6	Angioedema 01/2021 - 07/2009
5	Hereditary Angioedemas 01/2021 - 07/2009
3	Familial dermographism 01/2022 - 01/2017
3	Atopic Dermatitis (Atopic Eczema) 01/2022 - 01/2016
3	Skin Diseases (Skin Disease) 01/2022 - 03/2020
3	Asthma (Bronchial Asthma) 01/2020 - 07/2011
2	Hidradenitis Suppurativa 01/2022 - 01/2022
2	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2022 - 08/2019
2	COVID-19 01/2021 - 01/2020
2	Infections 01/2021 - 01/2020
2	Hypersensitivity (Allergy) 01/2020 - 07/2009
2	Cold Urticaria 01/2018 - 01/2017
1	Disorders of Excessive Somnolence (Hypersomnia) 03/2022
1	Pain (Aches) 01/2022
1	Autoimmune Diseases (Autoimmune Disease) 07/2021
1	Rhinosinusitis 01/2020
1	Nasal Polyps (Nasal Polyp) 01/2020
1	Erythema 11/2019
1	Tuberculosis (Tuberculoses) 08/2019
1	Psoriatic Arthritis 08/2019
1	Prurigo 04/2019
1	Dizziness (Lightheadedness) 11/2018
1	Hereditary Angioedema Types I and II 11/2018
1	Injection Site Reaction 11/2018
1	Mastocytosis 01/2018
1	Chronic Inducible Urticaria 01/2018
1	Mast-Cell Leukemia (Leukemia, Mast Cell) 01/2018
1	Mast-Cell Sarcoma 01/2018
1	Solar Urticaria 01/2018
1	Anaphylaxis (Anaphylactic Shock) 01/2016
1	Deglutition Disorders (Dysphagia) 01/2016
1	Edema (Dropsy) 03/2010

Drug/Important Bio-Agent (IBA)

16	Omalizumab (Xolair)FDA Link 03/2022 - 09/2010
8	Histamine Antagonists (Antihistamines)IBA 03/2022 - 01/2011
5	Immunoglobulin E (IgE)IBA 01/2022 - 07/2009
5	anti-IgE antibodiesIBA 12/2019 - 07/2011
3	Biological ProductsIBA 03/2022 - 01/2020
3	ligelizumabIBA 02/2022 - 10/2019
3	Monoclonal AntibodiesIBA 01/2022 - 11/2018
3	Anti-Bacterial Agents (Antibiotics)IBA 01/2022 - 08/2019
3	AutoantibodiesIBA 11/2021 - 07/2011
3	Immunoglobulin G (IgG)IBA 11/2021 - 12/2019
3	AntipruriticsIBA 04/2019 - 01/2016
2	Cholinergic Agents (Cholinergics)IBA 01/2022 - 01/2018
2	AntibodiesIBA 07/2021 - 07/2011
2	AllergensIBA 01/2021 - 07/2009
2	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 01/2021 - 01/2020
2	BradykininIBA 01/2020 - 01/2020
2	licochalcone AIBA 11/2019 - 07/2018
1	Non-Sedating Histamine H1 Antagonists (Histamine H1 Antagonists, Non Sedating)IBA 03/2022
1	antineoplaston A10 (A 10)IBA 03/2022
1	tralokinumabIBA 01/2022
1	nemolizumabIBA 01/2022
1	4-amino-4'-hydroxylaminodiphenylsulfone (HADS)IBA 01/2022
1	dupilumabIBA 01/2022
1	Clindamycin (Cleocin)FDA LinkGeneric 01/2022
1	SolutionsIBA 01/2022
1	Agammaglobulinaemia Tyrosine KinaseIBA 11/2021
1	fenebrutinibIBA 11/2021
1	Gonadal Steroid Hormones (Sex Hormones)IBA 10/2021
1	Antinuclear AntibodiesIBA 07/2021
1	A-factor (Streptomyces)IBA 03/2020
1	Biomarkers (Surrogate Marker)IBA 12/2019
1	Polidocanol (Laureth)FDA Link 11/2019
1	dexpanthenol (panthenol)FDA Link 11/2019
1	Urea (Carbamide)FDA LinkGeneric 11/2019
1	Leukotriene Antagonists (Leukotriene Receptor Antagonists)IBA 10/2019
1	Histamine (Histamine Dihydrochloride)FDA Link 04/2019
1	Aprepitant (Emend)FDA Link 04/2019
1	Plasma KallikreinIBA 11/2018
1	lanadelumabIBA 11/2018
1	Prednisolone (Predate)FDA LinkGeneric 01/2016
1	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2016
1	Complement C1 Inhibitor Protein (C1 Esterase Inhibitor)IBA 05/2015
1	Substance PIBA 11/2014
1	AutoantigensIBA 07/2011
1	Intravenous Immunoglobulins (IVIG)FDA Link 03/2010
1	Factor XII (Hageman Factor)IBA 07/2009
1	Danazol (Azol)FDA LinkGeneric 07/2009
1	Tranexamic Acid (AMCA)FDA Link 07/2009
1	Progesterone FDA LinkGeneric 07/2009

Therapy/Procedure

23	Therapeutics 03/2022 - 07/2009
1	Self Administration (Administration, Self) 01/2021
1	Complementary Therapies (Alternative Medicine) 08/2019
1	Tonsillectomy 08/2019
1	Intravenous Administration 01/2016